Kyverna Therapeutics, Inc.
mivocabtagene autoleucel
progressive multiple sclerosis
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for mivocabtagene autoleucel in progressive multiple sclerosis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Report additional data from Phase 1 IIT in 2026”